Among patients with previously treated HER2-positive metastatic breast cancer, those treated with pyrotinib plus capecitabine had a 31% lower risk for death than those treated with lapatinib and capecitabine, according to results from the phase 3 PHOEBE trial.
Overall survival (OS) was not reached in the pyrotinib arm compared with an OS of 26.9 months in the lapatinib arm. The findings were reported at the 2021 San Antonio Breast Cancer Symposium (abstract GS302).
“Among the patients